The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States.
Anita J BroganSandra E TalbirdAshley E DavisElizabeth M LaPrincy N KumarPublished in: PharmacoEconomics (2021)
Ibalizumab may represent a cost-effective and affordable option to improve health outcomes for individuals with MDR HIV-1 infection.